PIPELINE
Global Leader of Cancer Treatments
ATB-101
Combination drugs (Diabetes + hypertension Incrementally Modified Drug, IMD)
- Provides dose convenience to patients by developing IMD which treats diabetes and hypertension concurrently having the biggest market shares in global pharmaceutical market
- To improve drug compliance of elderly patients who suffer from above two chronic diseases and to reduce side effects from taking multiple drugs.
- Statistically improve anti-hypertensive effects were seen at a GLP facility (4 weeks study)
- Proven incremental efficacy of hypotensive effect in clinical trials will allow higher price
- An IMD suitable to go global
Key features
-
Confirmed incremental efficacy on hypertension
1) Patent granted in Nov. 2018 (KR), PCT applied in Sep. 2018
2) Non clinical efficacy study at a GLP facility confirmed synergistic effect (May 2018) - Formulation completed (July 2018)
- Toxicology – 4 week dose response study completed
- 13 week repeated dose toxicity study completed (Nov. 2018)
Development status
Results of improved efficacy using hypertensive rats (SHR) of
hypertension & diabetes combination drug
Efficacy results
-
G3·G4 vs G5
Compared to single anti-hypertension theraphy G5,
Hypertension+diabetes theraphy G3 and G4 showed
superior anti-hypertensive effect. -
G3 vs G6, G4 vs G7
Compared to single anti-diabetes theraphy G6 and G7,
Hypertension+diabetes therapy
G3 and G4 showed superior anti-hypertensive effect.